The 2019 meeting will again include representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Susan Kornstein and John Newcomer with representation of the sectors that are part of the ASCP community will lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, and academia comprise the 2019 Steering Committee. A Program Committee under the leadership of Drs. Anita Clayton and Erika Saunders will be responsible for review of all program submissions.
Registration for the meeting will open in December, 2018.